
Results
18
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
18 companies
Madrigal Pharmaceuticals
Market Cap: US$12.1b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$518.74
7D
-1.1%
1Y
62.1%
Insmed
Market Cap: US$31.2b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$143.83
7D
0.7%
1Y
108.6%
Ionis Pharmaceuticals
Market Cap: US$12.4b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$74.09
7D
-1.6%
1Y
150.6%
Alnylam Pharmaceuticals
Market Cap: US$41.2b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$313.79
7D
-2.0%
1Y
29.3%
Ascendis Pharma
Market Cap: US$14.3b
Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
ASND
US$225.00
7D
n/a
1Y
n/a
Neurocrine Biosciences
Market Cap: US$13.2b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$130.19
7D
1.4%
1Y
23.1%
BeOne Medicines
Market Cap: US$34.6b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$299.81
7D
-6.5%
1Y
17.0%
BridgeBio Pharma
Market Cap: US$14.4b
A biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
BBIO
US$71.67
7D
-7.5%
1Y
99.3%
AbbVie
Market Cap: US$354.6b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$200.95
7D
-3.8%
1Y
11.4%
Jazz Pharmaceuticals
Market Cap: US$12.5b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$199.96
7D
1.1%
1Y
83.5%
Eli Lilly
Market Cap: US$824.6b
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
LLY
US$917.65
7D
1.5%
1Y
6.7%
Natera
Market Cap: US$29.4b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$201.14
7D
2.6%
1Y
30.2%
Royalty Pharma
Market Cap: US$29.5b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$49.64
7D
2.4%
1Y
55.0%
Viatris
Market Cap: US$16.9b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$14.75
7D
5.3%
1Y
83.7%
Elanco Animal Health
Market Cap: US$11.2b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$22.39
7D
-3.2%
1Y
136.7%
Revvity
Market Cap: US$10.5b
Provides health sciences solutions, technologies, and services.
RVTY
US$87.15
7D
-2.7%
1Y
-8.4%
BioMarin Pharmaceutical
Market Cap: US$10.4b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$53.98
7D
-0.2%
1Y
-14.0%
Waters
Market Cap: US$32.8b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$311.20
7D
-2.5%
1Y
-8.7%